Ask the Expert Answers
Q&A: Dr. Anna Podolanczuk, MD
Dr. Podolanczuk is the Co-Director of the Weill Cornell Interstitial Lung Disease Program The following questions were submitted from Three Lakes 12-20 subscribers and followers as a part of our Ask the Expert series, where we provide a forum to industry professionals to widen access and education from those who are actively working towards the treatment and future of pulmonary fibrosis. The existing drugs are antifibrotics, and slow disease but do not stop progression. In terms of stopping...
Q&A: Dr. Andy Limper, MD
Dr. Limper is the Head of the Thoracic Research Unit at the Mayo Clinic in Rochester, Minnesota. The following questions were submitted from Three Lakes 12-20 subscribers and followers as a part of our Ask the Expert series , where we provide a forum to industry professionals to widen access and education from those who are actively working towards the treatment and future of pulmonary fibrosis. How does sleep apnea affect PF? Patients with idiopathic pulmonary fibrosis have a variety of...
Meet Our Expert
Dr. Toby Maher, MD, MSc, PhD, FRCP
Dr. Maher is the Professor of Medicine and Director of Interstitial Lung Disease at the Keck School of Medicine of USC University of Southern California
Dr. Maher has spent over 20 years specialising in the management of interstitial lung disease. Since June 2020 he has been Director of ILD at Keck Medicine of University of Southern California. He previously ran the ILD unit at Royal Brompton Hospital, London and was a Professor of ILD at Imperial College, London. His research interests include; biomarker discovery, cellular senescence in the pathogenesis of IPF and clinical trials.
He has been involved in >100 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, sarcoidosis, scleroderma, rheumatoid arthritis and inflammatory myositis. He is an associate editor for American Journal of Respiratory and Critical Care Medicine. He has authored over 420 papers on pulmonary fibrosis.
We will accept submissions for Ask the Expert with Dr. Maher through May 15th, 2026.
Answers will be published here on our website, so check back and stay subscribed to our email newsletter to stay updated!
Submit Your Questions
Ask the Expert
Advancing our mission means involving the scientific and industry professionals who are closest to the patients, research, and development opportunities.
In our Ask the Expert series, we will provide a form to submit questions to an identified Expert related to pulmonary fibrosis. Each month, we will introduce a new Expert.
Submit your questions, subscribe to our email list, and stay in touch to hear answers directly from our Expert!